696 related articles for article (PubMed ID: 15170637)
1. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
2. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.
Gerna G; Lilleri D; Caldera D; Furione M; Zenone Bragotti L; Alessandrino EP
Bone Marrow Transplant; 2008 May; 41(10):873-9. PubMed ID: 18209721
[TBL] [Abstract][Full Text] [Related]
3. A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients.
Lehto JT; Lemström K; Halme M; Lappalainen M; Lommi J; Sipponen J; Harjula A; Tukiainen P; Koskinen PK
Transpl Int; 2005 Dec; 18(12):1318-27. PubMed ID: 16297050
[TBL] [Abstract][Full Text] [Related]
4. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
[TBL] [Abstract][Full Text] [Related]
5. Monitoring human cytomegalovirus infection in transplant recipients.
Baldanti F; Lilleri D; Gerna G
J Clin Virol; 2008 Mar; 41(3):237-41. PubMed ID: 18203657
[TBL] [Abstract][Full Text] [Related]
6. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients.
Sanghavi SK; Abu-Elmagd K; Keightley MC; St George K; Lewandowski K; Boes SS; Bullotta A; Dare R; Lassak M; Husain S; Kwak EJ; Paterson DL; Rinaldo CR
J Clin Virol; 2008 Aug; 42(4):335-42. PubMed ID: 18495527
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
[TBL] [Abstract][Full Text] [Related]
8. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
Gerna G; Lilleri D; Zecca M; Alessandrino EP; Baldanti F; Revello MG; Locatelli F
Haematologica; 2005 Apr; 90(4):526-33. PubMed ID: 15820949
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
[TBL] [Abstract][Full Text] [Related]
10. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection.
Mengoli C; Cusinato R; Biasolo MA; Cesaro S; Parolin C; Palù G
J Med Virol; 2004 Sep; 74(1):78-84. PubMed ID: 15258972
[TBL] [Abstract][Full Text] [Related]
11. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value.
Martín-Dávila P; Fortún J; Gutiérrez C; Martí-Belda P; Candelas A; Honrubia A; Barcena R; Martínez A; Puente A; de Vicente E; Moreno S
J Clin Virol; 2005 Jun; 33(2):138-44. PubMed ID: 15911429
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients.
Gerna G; Percivalle E; Baldanti F; Sarasini A; Zavattoni M; Furione M; Torsellini M; Revello MG
New Microbiol; 1998 Jul; 21(3):293-308. PubMed ID: 9699213
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
Hebart H; Rudolph T; Loeffler J; Middeldorp J; Ljubicic T; Jahn G; Einsele H
Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537
[TBL] [Abstract][Full Text] [Related]
14. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
[TBL] [Abstract][Full Text] [Related]
15. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients.
Gerna G; Baldanti F; Lilleri D; Parea M; Alessandrino E; Pagani A; Locatelli F; Middeldorp J; Revello MG
J Clin Microbiol; 2000 May; 38(5):1845-53. PubMed ID: 10790111
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cytomegalovirus viral load measure by real-time PCR with pp65 antigenemia for the diagnosis of cytomegalovirus disease in solid organ transplant patients.
Hernando S; Folgueira L; Lumbreras C; San Juan R; Maldonado S; Prieto C; Babiano MJ; Delgado J; Andres A; Moreno E; Aguado JM; Otero JR
Transplant Proc; 2005 Nov; 37(9):4094-6. PubMed ID: 16386635
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of human cytomegalovirus in recipients of solid organ transplants by real-time quantitative PCR and pp65 antigenemia.
Mengelle C; Pasquier C; Rostaing L; Sandres-Sauné K; Puel J; Berges L; Righi L; Bouquies C; Izopet J
J Med Virol; 2003 Feb; 69(2):225-31. PubMed ID: 12683412
[TBL] [Abstract][Full Text] [Related]
18. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
20. Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia.
Pillet A; Mengelle C; Basse G; Ribes D; Kamar N; Muscari F; Lavayssière L; Suc B; Esposito L; Peron JM; Rostaing L
Transplant Proc; 2006 Sep; 38(7):2335-8. PubMed ID: 16980083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
